Heat Biologics, Inc. (NASDAQ:HTBX) Files An 8-K Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure.

Heat Biologics, Inc. (the Company) will be making an investor
presentation at the Biotech Showcase 2017 Conference on
Wednesday, January 11, 2017, at 9:30 a.m. Pacific Standard Time
at the Hilton San Francisco Union Square in San Francisco,
California and additional presentations over the next few weeks.
In connection with the presentations, the Company intends to
discuss the updated slide presentation furnished as Exhibit 99.1
hereto, which is incorporated herein by reference.

The slide presentation attached as Exhibit 99.1 to this Current
Report on Form 8-K includes safe harbor language to the Private
Securities Litigation Reform Act of 1995, as amended, indicating
that certain statements contained in the slide presentation are
forward-looking rather than historical.

The information included in this Item 7.01 and in Exhibit 99
shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities of that Section or
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such filing. The
Company undertakes no duty or obligation to update or revise
information included in this Current Report on Form 8-K or any of
the Exhibits.

Item 9.01 Financial Statements and Exhibits.

About Heat Biologics, Inc. (NASDAQ:HTBX)

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.

Heat Biologics, Inc. (NASDAQ:HTBX) Recent Trading Information

Heat Biologics, Inc. (NASDAQ:HTBX) closed its last trading session up +0.071 at 0.951 with 3,833,115 shares trading hands.